Dasher Neuroscience achève le recrutement des patients dans le cadre de l'essai clinique mondial de phase II portant sur le YA-101, son principal candidat-médicament développé grâce à l'IA, destiné au traitement de l'atrophie multisystématisée (AMS)

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience completed patient recruitment for a global Phase II trial of YA-101, an AI-discovered candidate drug for treating multiple system atrophy (MSA). The company is a biotech firm focused on AI-driven drug discovery for central nervous system disorders.

Clinical Trial Data

Phase

Phase II

Outcome Details

Patient recruitment completed in global Phase II clinical trial

Importance:5/10

Sentiment:

0.50

clinical trialPhase IIAI-discovered drugCNSpatient recruitment

Related Companies

$7829

Read the original article

Published by PR Newswire Pharma on July 29, 2026 7:01 AM

Read Original